Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liangxue Tongyu Fang plus atorvastatin in hemorrhagic moyamoya disease
NCT07894640Phase 1Enrolling by invitation
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Dec 2024
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in Moyamoya disease, sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Percentage of Participants With an Increase of at Least 1 Point in Cerebral Perfusion Staging at 12 weeks. Started Dec 2024; status: enrolling by invitation.
02
Conditions
Moyamoya disease
Beyond the preview
Go deeper on NCT07894640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07894640.